Perioperative Therapies in Locally Advanced Unresectable Gastric Cancer

Gastric cancer (GC) is the fifth most commonly diagnosed cancer, with over one million cases diagnosed annually worldwide. Human epidermal growth factor receptor 2 (HER2) overexpression in GC (seen in 4.4% to 53.4% of patients in different reports) is predictive biomarker of response to HER2-targeting therapies. Trastuzumab in combination with cisplatin or oxaliplatin, and a fluoropyrimidine (capecitabine or 5-fluorouracil \[5-FU\]), is approved anti-HER2 therapy for first-line treatment of HER2-positive gastric or gastroesophageal junction (GEJ) cancer. Rilvegostomig 750 mg Q3W was selected

Trial Details

NCT ID
NCT06630130
Phase
PHASE2
Sponsor
Jeeyun Lee
Status
RECRUITING
Cancer Type
Gastroesophageal Junction (GEJ) Gastric Cancer
Interventions
  • Trastuzumab deruxtecan
  • Capecitabine
  • Rilvegostomig
  • Durvalumab
  • Sonesitatug Vedotin
  • Oxaliplatin
Locations (sample)
  • Seoul, South Korea|37.566,126.9784

Key Eligibility Criteria

  • Provision of fully informed consent prior to any study specific procedures.
  • Patients must be ≥ 19 years of age
  • Have a life expectancy of at least 12 weeks
  • Body weight \> 30kg( \> 35kg for Rilvegostomig)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastroesophageal Junction (GEJ) Gastric Cancer Trials on Trialify →